Abramowitz Jessica, Tangpricha Vin
Division of Endocrinology and Metabolism, Department of Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9302, USA.
Division of Endocrinology, Metabolism & Lipids, Department of Medicine, Emory University School of Medicine, 101 Woodruff Circle NE-WMRB 1301, Atlanta, GA 30322, USA.
Clin Plast Surg. 2018 Jul;45(3):313-317. doi: 10.1016/j.cps.2018.03.003.
Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur with estradiol therapy include breast development, body fat redistribution, and decreased muscle mass. Transfeminine treatment regimens require monitoring and dose adjustments to achieve appropriate physiologic targets to enhance feminization and decrease risk of adverse outcomes. Adverse effects associated with estradiol use include thromboembolic disease, macroprolactinoma, breast cancer, coronary artery disease, cerebrovascular disease, cholelithiasis, and hypertriglyceridemia. Benefits of hormonal treatment may include both an improvement in quality of life and a decrease in gender dysphoria.
跨性别女性个体接受雌二醇和抗雄激素药物治疗，以转变为更女性化的外表。雌二醇治疗所发生的身体变化包括乳房发育、身体脂肪重新分布以及肌肉量减少。跨性别女性的治疗方案需要监测和剂量调整，以实现适当的生理目标，增强女性化并降低不良后果的风险。与使用雌二醇相关的不良反应包括血栓栓塞性疾病、大泌乳素瘤、乳腺癌、冠状动脉疾病、脑血管疾病、胆石症和高甘油三酯血症。激素治疗的益处可能包括生活质量的改善和性别焦虑症的减轻。
